Journal
CANCER INVESTIGATION
Volume 30, Issue 5, Pages 415-421Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2012.675381
Keywords
Kidney cancer; Tumor suppressor gene; DNA methylation; CpG; DNMT; Interferon; MG98
Categories
Funding
- MethylGene Inc.
Ask authors/readers for more resources
Background: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production. Methods: This multicenter study explored two schedules of MG98 with Interferon-alpha-2 beta to identify schedule and dose for patients with metastatic RCC. Results: Doses of IFN 9 MIU/MG98 125 mg/m(2) for a continuous schedule and IFN 9 MIU/MG98 200 mg/m(2) for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD. Conclusion: MG98 combined with IFN was safe and resulted in clinical activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available